Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retifanlimab - Incyte Corporation/MacroGenics

Next Previous
Drug Profile

Retifanlimab - Incyte Corporation/MacroGenics

Alternative Names: AEX-1188; INCMGA-0012; INCMGA00012; MGA-012; Retifanlimab-dlwr; Zynyz

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer BriaCell Therapeutics Corp; Incyte Corporation; MacroGenics; University of Washington; ZAI Lab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer; Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma
  • Preregistration Squamous cell cancer
  • Phase III Endometrial cancer; Non-small cell lung cancer
  • Phase II/III Gastric cancer; Oesophageal cancer
  • Phase II Adenosquamous carcinoma; Bladder cancer; Glioblastoma; Glioma; Head and neck cancer; Liposarcoma; Pancreatic cancer; Penile cancer; Sarcoma; Solid tumours; Triple negative breast cancer
  • Phase I/II Breast cancer; Colorectal cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I Adenocarcinoma
  • No development reported Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

  • 08 Mar 2024 Retifanlimab is still in phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04580485)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 22 Feb 2024 Incyte Corporation completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, France, Italy, Spain, United Kingdom and the US (IV) (NCT04580485)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top